NCT07079267|Unknown
Olpasiran Expanded Access Program
1 other identifier
Olpasiran Expanded Access
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredJul 2025
Brief Summary
Expanded access requests for Olpasiran may be considered for adult participants with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD). To request access, use Responsible Party contact information provided in this record.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 14, 2025
Completed9 days until next milestone
First Posted
Study publicly available on registry
July 23, 2025
CompletedLast Updated
July 23, 2025
Status Verified
July 1, 2025
First QC Date
July 14, 2025
Last Update Submit
July 14, 2025
Interventions
OlpasiranDRUG
Eligibility Criteria
Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Amgenlead
MeSH Terms
Interventions
olpasiran
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 14, 2025
First Posted
July 23, 2025
Last Updated
July 23, 2025
Record last verified: 2025-07